Vaccination COVID-19 chez les donneurs de sang indiens: évaluer l'impact sur la période de report.

The only efficacious way to provide people with herd immunity against the novel corona virus [nCoV] is to administer an appropriate vaccine and help check the current pandemic. With the genetic sequence data of the nCoV already available since January 10, 2020, leading pharmaceutical companies, world over, in turn, have started working on the clinical trials to produce vaccines against this nCoV. In fact, many vaccines under the Phase III trial have claimed to demonstrate their efficacy as high as 95% against nCoV. In India as of now, two vaccines have been licensed namely, Covishield (Live vaccine, Oxford AstraZeneca, United Kingdom) and Covaxin (inactivated vaccine, Bharat Biotech, India). Although, most of the countries offer no deferral period for the donors who have been administered an inactivated vaccine against this nCoV. However, the national blood transfusion council of India has recently recommended a donor deferral period of 28 days from the last dose of vaccination. This could essentially lead to a massive loss of eligible blood donors and jeopardise the already disrupted blood supply management due to the COVID-19 outbreak. The authors herein, propose a thorough redefining of this deferral period post-vaccination amongst the Indian blood donors.